Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.

MLA

Kazda, Christof M., et al. “Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.” Diabetes Care, vol. 40, no. 6, June 2017, p. 808. EBSCOhost, https://doi.org/10.2337/dc17-er06.

APA

Kazda, C. M., Ding, Y., Kelly, R. P., Garhyan, P., Shi, C., Lim, C. N., Fu, H., Watson, D. E., Lewin, A. J., Landschulz, W. H., Deeg, M. A., Moller, D. E., & Hardy, T. A. (2017). Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249. Diabetes Care, 40(6), 808. https://doi.org/10.2337/dc17-er06

Chicago

Kazda, Christof M, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, et al. 2017. “Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.” Diabetes Care 40 (6): 808. doi:10.2337/dc17-er06.